Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 2 results out of 2
Data Insights
Sarilumab by Regeneron Pharmaceuticals for Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease): Likelihood of Approval
Sarilumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease)....
Data Insights
Sarilumab by Regeneron Pharmaceuticals for Polyarticular Juvenile Idiopathic Arthritis (PJIA): Likelihood of Approval
Sarilumab is under clinical development by Regeneron Pharmaceuticals and currently in Pre-Registration for Polyarticular Juvenile Idiopathic Arthritis (PJIA). According to...